Israel's Sol-Gel signs Canadian licensing deal for Twyneo, Epsolay

Israel's Sol-Gel (NASDAQ:SLGL) has signed an exclusive licensing deal with Searchlight Pharma for the Canadian commercialization rights to its dermatology products Twyneo and Epsolay.

Sol-Gel said it will receive up to $11M in upfront and milestone payments for the rights, plus royalties on net sales ranging from the low double-digits to high teens. The deal is for 15 years and is renewable in five-year periods.

Acne drug Twyneo and rosacea treatment Epsolay were both recently launched in the US. Sol-Gel licensed exclusive commercialization rights to the products in the US to Galderma.

More on Sol-Gel:

Sol-Gel Technologies GAAP EPS of -$0.41

Sol-Gel to acquire rare disorder drug patidegib for $4.7M upfront; plans $22.8M offerings